Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2016 Q1- Text added to 2016 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
abandon, adjunct, antiemetic, comparison, consumption, dose, double, easier, foundation, GlaxoSmithKline, Helsinn, Hesketh, Hospira, incision, infiltration, instillation, Kabi, Kirin, Kyowa, lend, lien, longer, Marcaine, Mayo, mg, milestone, Naropin, pivotal, plc, preliminary, proceeding, Promissory, puncture, replicated, Roche, ropivacaine, route, safer, served, solution, TCM, USA, wound
Removed:
amend, broadening, designated, exercisable, issuable, pharmacology, remain, surrender, waiver, working
Valuein 2016 Q1 filing- Value in 2016 Q2 filing
Original filings
Filing view